Literature DB >> 18778305

Protease-activated receptor dependent and independent signaling by kallikreins 1 and 6 in CNS neuron and astroglial cell lines.

Alexander G Vandell1, Nadya Larson, Gurunathan Laxmikanthan, Michael Panos, Sachiko I Blaber, Michael Blaber, Isobel A Scarisbrick.   

Abstract

While protease-activated receptors (PARs) are known to mediate signaling events in CNS, contributing both to normal function and pathogenesis, the endogenous activators of CNS PARs are poorly characterized. In this study, we test the hypothesis that kallikreins (KLKs) represent an important pool of endogenous activators of CNS PARs. Specifically, KLK1 and KLK6 were examined for their ability to evoke intracellular Ca(2+) flux in a PAR-dependent fashion in NSC34 neurons and Neu7 astrocytes. Both KLKs were also examined for their ability to activate mitogen-activated protein kinases (extracellular signal-regulated kinases, C-Jun N-terminal kinases, and p38) and protein kinase B (AKT) intracellular signaling cascades. Cumulatively, these studies show that KLK6, but not KLK1, signals through PARs. KLK6 evoked intracellular Ca(2+) flux was mediated by PAR1 in neurons and both PAR1 and PAR2 in astrocytes. Importantly, both KLK1 and KLK6 altered the activation state of mitogen-activated protein kinases and AKT, suggestive of important roles for each in CNS neuron and glial differentiation, and survival. The cellular specificity of CNS-KLK activity was underscored by observations that both proteases promoted AKT activation in astrocytes, but inhibited such signaling in neurons. PAR1 and bradykinin receptor inhibitors were used to demonstrate that KLK1-mediated activation of extracellular signal-regulated kinases in neurons occurred in a non-PAR, bradykinin 2 (B2) receptor-dependent fashion, while similar signaling by KLK6 was mediated by the combined activation of PAR1 and B2. Cumulatively results indicate KLK6, but not KLK1 is an activator of CNS PARs, and that both KLKs are poised to signal in a B2 receptor-dependent fashion to regulate multiple signal transduction pathways relevant to CNS physiologic function and dysfunction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18778305      PMCID: PMC2692621          DOI: 10.1111/j.1471-4159.2008.05658.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  84 in total

1.  Bradykinin antagonists reduce leukocyte-endothelium interactions after global cerebral ischemia.

Authors:  Jens Lehmberg; Jürgen Beck; Alexander Baethmann; Eberhard Uhl
Journal:  J Cereb Blood Flow Metab       Date:  2003-04       Impact factor: 6.200

2.  Delayed argatroban treatment reduces edema in a rat model of intracerebral hemorrhage.

Authors:  Takuji Kitaoka; Ya Hua; Guohua Xi; Julian T Hoff; Richard F Keep
Journal:  Stroke       Date:  2002-12       Impact factor: 7.914

3.  Tissue kallikrein actions at the rabbit natural or recombinant kinin B2 receptors.

Authors:  Steeve Houle; Giuseppe Molinaro; Albert Adam; François Marceau
Journal:  Hypertension       Date:  2003-02-03       Impact factor: 10.190

4.  Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system.

Authors:  Matthew J Bernett; Sachiko I Blaber; Isobel A Scarisbrick; Pushparani Dhanarajan; Steven M Thompson; Michael Blaber
Journal:  J Biol Chem       Date:  2002-04-30       Impact factor: 5.157

5.  Thrombin (PAR-1)-induced proliferation in astrocytes via MAPK involves multiple signaling pathways.

Authors:  Hong Wang; Joachim J Ubl; Rolf Stricker; Georg Reiser
Journal:  Am J Physiol Cell Physiol       Date:  2002-11       Impact factor: 4.249

6.  Up-regulation of proteinase-activated receptor 1 expression in astrocytes during HIV encephalitis.

Authors:  Leonie A Boven; Nathalie Vergnolle; Scot D Henry; Claudia Silva; Yoshinori Imai; Janet Holden; Kenneth Warren; Morley D Hollenberg; Christopher Power
Journal:  J Immunol       Date:  2003-03-01       Impact factor: 5.422

7.  Increase of prothrombin-mRNA after global cerebral ischemia in rats, with constant expression of protease nexin-1 and protease-activated receptors.

Authors:  M Riek-Burchardt; F Striggow; P Henrich-Noack; G Reiser; K G Reymann
Journal:  Neurosci Lett       Date:  2002-08-30       Impact factor: 3.046

8.  Thrombin-induced microglial activation produces degeneration of nigral dopaminergic neurons in vivo.

Authors:  Sang-H Choi; Eun H Joe; Seung U Kim; Byung K Jin
Journal:  J Neurosci       Date:  2003-07-02       Impact factor: 6.167

9.  Decreased concentration of human kallikrein 6 in brain extracts of Alzheimer's disease patients.

Authors:  Maryam Zarghooni; Antoninus Soosaipillai; Linda Grass; Andreas Scorilas; Nader Mirazimi; Eleftherios P Diamandis
Journal:  Clin Biochem       Date:  2002-05       Impact factor: 3.281

10.  A role for ERK MAP kinase in physiologic temporal integration in hippocampal area CA1.

Authors:  Joel C Selcher; Edwin J Weeber; Jill Christian; Tanya Nekrasova; Gary E Landreth; J David Sweatt
Journal:  Learn Mem       Date:  2003 Jan-Feb       Impact factor: 2.460

View more
  33 in total

1.  Kallikrein 6 is a novel molecular trigger of reactive astrogliosis.

Authors:  Isobel A Scarisbrick; Maja Radulovic; Joshua E Burda; Nadya Larson; Sachiko I Blaber; Caterina Giannini; Michael Blaber; Alexander G Vandell
Journal:  Biol Chem       Date:  2012-04       Impact factor: 3.915

2.  Genetic targeting of protease activated receptor 2 reduces inflammatory astrogliosis and improves recovery of function after spinal cord injury.

Authors:  Maja Radulovic; Hyesook Yoon; Jianmin Wu; Karim Mustafa; Michael G Fehlings; Isobel A Scarisbrick
Journal:  Neurobiol Dis       Date:  2015-08-24       Impact factor: 5.996

3.  Differential expression of multiple kallikreins in a viral model of multiple sclerosis points to unique roles in the innate and adaptive immune response.

Authors:  Michael Panos; George P Christophi; Moses Rodriguez; Isobel A Scarisbrick
Journal:  Biol Chem       Date:  2014-09       Impact factor: 3.915

4.  Critical role for PAR1 in kallikrein 6-mediated oligodendrogliopathy.

Authors:  Joshua E Burda; Maja Radulovic; Hyesook Yoon; Isobel A Scarisbrick
Journal:  Glia       Date:  2013-07-08       Impact factor: 7.452

5.  Kallikrein cascades in traumatic spinal cord injury: in vitro evidence for roles in axonopathy and neuron degeneration.

Authors:  Maja Radulovic; Hyesook Yoon; Nadya Larson; Jianmin Wu; Rachel Linbo; Joshua E Burda; Eleftherios P Diamandis; Sachiko I Blaber; Michael Blaber; Michael G Fehlings; Isobel A Scarisbrick
Journal:  J Neuropathol Exp Neurol       Date:  2013-11       Impact factor: 3.685

Review 6.  Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function.

Authors:  Ervin G Erdös; Fulong Tan; Randal A Skidgel
Journal:  Hypertension       Date:  2010-01-11       Impact factor: 10.190

Review 7.  Protease-activated receptors in kidney disease progression.

Authors:  Oleg Palygin; Daria V Ilatovskaya; Alexander Staruschenko
Journal:  Am J Physiol Renal Physiol       Date:  2016-10-12

8.  The thrombin receptor is a critical extracellular switch controlling myelination.

Authors:  Hyesook Yoon; Maja Radulovic; Kristen L Drucker; Jianmin Wu; Isobel A Scarisbrick
Journal:  Glia       Date:  2015-01-27       Impact factor: 7.452

9.  PAR1 and PAR2 couple to overlapping and distinct sets of G proteins and linked signaling pathways to differentially regulate cell physiology.

Authors:  Kelly L McCoy; Stephen F Traynelis; John R Hepler
Journal:  Mol Pharmacol       Date:  2010-03-09       Impact factor: 4.436

10.  Kallikrein-related peptidase-6 (KLK6) mRNA expression is an independent prognostic tissue biomarker of poor disease-free and overall survival in colorectal adenocarcinoma.

Authors:  Spyridon Christodoulou; Dimitra K Alexopoulou; Christos K Kontos; Andreas Scorilas; Iordanis N Papadopoulos
Journal:  Tumour Biol       Date:  2014-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.